Chikungunya Virus Capsid Antibody - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-13436
Key Product Details
Species Reactivity
Virus
Applications
Western Blot, Immunocytochemistry/ Immunofluorescence
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Format
BSA Free
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Recombinant protein encompassing a sequence within the N-terminus region of Chikungunya Virus Capsid. The exact sequence is proprietary.
Reactivity Notes
Chikungunya Virus
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Description
Centrifuge briefly prior to opening.
Scientific Data Images for Chikungunya Virus Capsid Antibody - BSA Free
Immunocytochemistry/ Immunofluorescence: Chikungunya Virus Capsid Antibody [NBP3-13436]
Immunocytochemistry/Immunofluorescence: Chikungunya Virus Capsid Antibody [NBP3-13436] - Chikungunya Virus Capsid antibody detects Chikungunya Virus Capsid protein at cytoplasm by immunofluorescent analysis. Sample: Mock and transfected 293T cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: Chikungunya Virus Capsid stained by Chikungunya Virus Capsid antibody (NBP3-13436) diluted at 1:2000.Western Blot: Chikungunya Virus Capsid Antibody [NBP3-13436]
Western Blot: Chikungunya Virus Capsid Antibody [NBP3-13436] - Non-transfected (-) and transfected (+) 293T whole cell extracts (30 ug) were separated by 12% SDS-PAGE, and the membrane was blotted with Chikungunya Virus Capsid antibody (NBP3-13436) diluted at 1:5000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.Western Blot: Chikungunya Virus Capsid Antibody [NBP3-13436] -
Chikungunya viral lysate (0.5 ug) was separated by 12% SDS-PAGE, and the membrane was blotted with Chikungunya virus Capsid antibody (NBP3-13436) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.Applications for Chikungunya Virus Capsid Antibody - BSA Free
Application
Recommended Usage
Immunocytochemistry/ Immunofluorescence
Assay dependent
Western Blot
1:1000-1:10000
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Formulation
PBS, 20% Glycerol
Format
BSA Free
Preservative
0.025% Proclin 300
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: Chikungunya Virus Capsid
Although analysis suggests CHIKV originated in Africa over 500 years ago, first infections weren't reported until the 1950s (1-3). CHIKV has evolved three distinct genotypes, or strains, based on location, termed West African (WA), East/Central/Southern African (ECSA), and Asian (2-3). The WA strain has been most closely associated with enzootic transmission whereas the ECSA strain contributes more to urban epidemics (2). Nonhuman primates are the primary reservoir for the viral host with transmission occurring via mosquitos biting and infecting humans (1-3). Upon acute infection, the virus replicates in cells including fibroblasts and macrophages resulting in innate immune response in infected tissues characterized by infiltrating cells like macrophages, monocytes, natural killer (NK) cells, and lymphocytes (2,3). Infection results in increased production of proinflammatory cytokines such as interferon alpha (IFN-alpha) and interleukin 6 (IL-6), chemokines, and growth factors (2,3). Physical manifestations of infection are high fever, polyarthralgia, headache, arthritis, and rash (1-3). CHIKV symptoms can be confused with other infections like those from dengue fever and Zika virus (1-3). There are no specific antivirals or vaccines for CHIKV, but rather symptoms are treated with antipyretics and non-steroidal anti-inflammatory drugs (NSAIDs) (2,3). While in vitro culture models and in vivo rodent and non-human primate models have been used to study CHIKV pathogenesis and advance our knowledge of the disease, the specific cellular mechanisms are not fully understood (3).
References
1. Vu DM, Jungkind D, Angelle Desiree LaBeaud. Chikungunya Virus. Clin Lab Med. 2017;37(2):371-382. https://doi.org/10.1016/j.cll.2017.01.008
2. Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017;127(3):737-749. https://doi.org/10.1172/JCI84417
3. Ganesan VK, Duan B, Reid SP. Chikungunya Virus: Pathophysiology, Mechanism, and Modeling. Viruses. 2017;9(12):368. Published 2017 Dec 1. https://doi.org/10.3390/v9120368
Alternate Names
C protein, Chikungunya Virus Capsid Protein, Coat protein
Additional Chikungunya Virus Capsid Products
Product Documents for Chikungunya Virus Capsid Antibody - BSA Free
Product Specific Notices for Chikungunya Virus Capsid Antibody - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...